Comorbidity and Survival in Lung Cancer Patients

Islam, K. M.; Jiang, Xiaohui; Anggondowati, Trisari; Lin, Ge; Ganti, Apar Kishor

doi:10.1158/1055-9965.epi-15-0036

Cited by 156 publications

(143 citation statements)

References 27 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…This proportion is somewhat higher than that found in a recent large study of 5683 patients with lung cancer, in which renal disease was recorded in 5.7% of patients [19]. This might be explained by the fact that we investigated lung cancer patients with bone metastasis which was already present at the time of diagnosis in 40% of the patients.…”

Section: Discussioncontrasting

confidence: 63%

Renal Impairment Hampers Bisphosphonate Treatment in a Quarter of Lung Cancer Patients with Bone Metastasis

Fábián

Puskás

Kakuk

et al. 2017

Basic Clin Pharmacol Toxicol

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 63%

Renal Impairment Hampers Bisphosphonate Treatment in a Quarter of Lung Cancer Patients with Bone Metastasis

Fábián

Puskás

Kakuk

et al. 2017

Basic Clin Pharmacol Toxicol

View full text Add to dashboard Cite

“…Most cases of lung cancer are diagnosed in their advanced stages, compromising long-term survival (1-year survival rate of ∼10%) [2]. Platinum-based therapy is the recommended first-line treatment for advanced NSCLC.…”

mentioning

confidence: 99%

Biodistribution and Pharmacokinetics of Mad2 siRNA-loaded EGFR-Targeted Chitosan Nanoparticles in Cisplatin Sensitive and Resistant Lung Cancer Models

Nascimento

Gattacceca

Singh

et al. 2016

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Background: The present study focuses on biodistribution profile and pharmacokinetic parameters of EGFR-targeted chitosan nanoparticles (TG CS nanoparticles) for siRNA/cisplatin combination therapy of lung cancer. Material & methods: Mad2 siRNA was encapsulated in EGFR targeted and nontargeted (NTG) CS nanoparticles by electrostatic interaction. The biodistribution of the nanoparticles was assessed qualitatively and quantitatively in cisplatin (DDP) sensitive and resistant lung cancer xenograft model. Results: TG nanoparticles showed a consistent and preferential tumor targeting ability with rapid clearance from the plasma to infiltrate and sustain within the tumor up to 96 h. They exhibit a sixfold higher tumor targeting efficiency compared with the NTG nanoparticles. Conclusion: TG nanoparticles present as an attractive drug delivery platform for RNAi therapeutics against NSCLC.

show abstract

“…Variations in the distribution of stage at diagnosis (resulting from different screening and early-detection practices) can influence overall relative survival (all stages combined), and differences in treatment options or access to care (or both) can affect relative survival both overall and by stage 9,10 . Comorbidities can also influence patient outcomes 11,12 .…”

Section: Discussionmentioning

confidence: 99%

A First Look at Relative Survival by Stage for Colorectal and Lung Cancers in Canada

et al. 2016

View full text Add to dashboard Cite

Monitoring and reporting on cancer survival provides a mechanism for understanding the effectiveness of Canada's cancer care system. Although 5-year relative survival for colorectal cancer and lung cancer has been previously reported, only recently has pan-Canadian relative survival by stage been analyzed using comprehensive registry data. This article presents a first look at 2-year relative survival by stage for colorectal and lung cancer across 9 provinces.As expected, 2-year age-standardized relative survival ratios (arsrs) for colorectal cancer and lung cancer were higher when the cancer was diagnosed at an earlier stage. The arsrs for stage i colorectal cancer ranged from 92.2% in Nova Scotia [95% confidence interval (ci): 88.6% to 95.1%] to 98.4% in British Columbia (95% ci: 96.2% to 99.3%); for stage iv, they ranged from 24.3% in Prince Edward Island (95% ci: 15.2% to 34.4%) to 38.8% in New Brunswick (95% ci: 33.3% to 44.2%). The arsrs for stage i lung cancer ranged from 66.5% in Prince Edward Island (95% ci: 54.5% to 76.5%) to 84.8% in Ontario (95% ci: 83.5% to 86.0%). By contrast, arsrs for stage iv lung cancer ranged from 7.6% in Manitoba (95% ci: 5.8% to 9.7%) to 13.2% in British Columbia (95% ci: 11.8% to 14.6%).The available stage data are too recent to allow for meaningful comparisons between provinces, but over time, analyzing relative survival by stage can provide further insight into the known differences in 5-year relative survival. As the data mature, they will enable an assessment of the extent to which interprovincial differences in relative survival are influenced by differences in stage distribution or treatment effectiveness (or both), permitting targeted measures to improve population health outcomes to be implemented.

show abstract

Comorbidity and Survival in Lung Cancer Patients

Cited by 156 publications

References 27 publications

Renal Impairment Hampers Bisphosphonate Treatment in a Quarter of Lung Cancer Patients with Bone Metastasis

Renal Impairment Hampers Bisphosphonate Treatment in a Quarter of Lung Cancer Patients with Bone Metastasis

Biodistribution and Pharmacokinetics of Mad2 siRNA-loaded EGFR-Targeted Chitosan Nanoparticles in Cisplatin Sensitive and Resistant Lung Cancer Models

A First Look at Relative Survival by Stage for Colorectal and Lung Cancers in Canada

Contact Info

Product

Resources

About